The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).
Fabrice Barlesi
No relevant relationships to disclose
Helene Blons
No relevant relationships to disclose
Michele Beau-Faller
No relevant relationships to disclose
Isabelle Rouquette
No relevant relationships to disclose
L'houcine Ouafik
No relevant relationships to disclose
Jean Mosser
No relevant relationships to disclose
Jean-Philippe Merlio
No relevant relationships to disclose
Pierre Paul Bringuier
No relevant relationships to disclose
Philippe Jonveaux
No relevant relationships to disclose
Cedric Le Marechal
No relevant relationships to disclose
Marc G. Denis
No relevant relationships to disclose
Frederique Madeleine Penault-Llorca
No relevant relationships to disclose
Didier Debieuvre
No relevant relationships to disclose
Jean-Charles Soria
No relevant relationships to disclose
Jacques Cadranel
No relevant relationships to disclose
Julien Mazieres
No relevant relationships to disclose
Pascale Missy
No relevant relationships to disclose
Franck Morin
No relevant relationships to disclose
Frederique Nowak
No relevant relationships to disclose
Gerard Zalcman
No relevant relationships to disclose